TD Cowen downgrades Jasper Therapeutics stock rating to Hold

TD Cowen downgraded Jasper Therapeutics to Hold from Buy, citing major funding uncertainty, with only $14 million in cash, an $11 million Q1 burn rate, and roughly one to two quarters of runway. The firm said briquilimab remains 2.5 to 3 years behind schedule, faces intensifying CSU competition, and carries patent protection limits, even as the company awaits FDA feedback on its updated Phase 2b protocol within 60 days. Shares have already fallen 80% over the past year to $0.96, underscoring the strain on the stock.

Analysis

JSPR is drifting into the classic biotech death spiral: high binary regulatory dependence, a short cash runway, and no visible financing bridge. The market is effectively valuing the equity as an option on a near-term FDA reply plus a rescue financing, but with the stock already deeply impaired, any new capital likely comes in highly dilutive or via structured terms that further cap upside for existing holders.

The more important second-order issue is competitive slippage. Even if the protocol amendment solves the underdosing issue, the delay pushes the asset further behind a crowded CSU landscape where commercial incumbents and better-capitalized development programs can lock up prescriber attention and payer contracts before briquilimab is ready. In this setup, the regulatory update is a catalyst only if it leads immediately to a financing package; otherwise it can become a trap rally as short-term traders buy the headline while fundamentals continue to deteriorate.

The patent angle is also not fully supportive: late-2027 composition expiry leaves little room for a slow launch cycle, especially if the company loses another 6-12 months to cash preservation or trial redesign. That makes the strategic value of the asset highly path-dependent and reduces M&A optionality, because acquirers typically want more time to monetize exclusivity or de-risk the class-specific safety concerns.

Consensus may be underestimating how asymmetric the timing risk is: the next 30-60 days matter far more than the underlying science over the next 2-3 years. If funding does not arrive alongside FDA feedback, the equity can gap lower again on going-concern concerns; if financing does arrive, existing holders still face a likely reset in ownership economics. This is less a fundamental long idea than a tradeable volatility event with negative carry for longs.

Key Decisions for Investors

• Avoid outright long JSPR; if holding legacy shares, reduce into any FDA-driven bounce over the next 2-4 weeks because financing risk likely transfers value from equity to new capital.
• For event-driven shorts, consider a small short position in JSPR ahead of the expected FDA window, with a tight stop above a financing-led squeeze; the risk/reward favors downside if no capital solution is announced.
• Use put spreads rather than naked puts in JSPR for the next 1-2 months to express downside while limiting premium burn; target a move back below sub-$0.75 if dilution risk reasserts.
• If the stock rallies sharply on protocol approval, pair short JSPR against a basket of better-capitalized allergy/immunology names to isolate idiosyncratic funding risk rather than broader sector beta.